TSVT News and Press, 2seventy bio Inc. From 09/12/23

2023-09-12 07:59:29 ET More on 2seventy bio Seeking Alpha’s Quant Rating on 2seventy bio Historical earnings data for 2seventy bio Financial information for 2seventy bio 2seventy bio: Nothing Properly Explains The Low Valuation 2seventy bio dow...

Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on long-term mission Company to internally advance fewer pipeline programs while expanding colla...

Initial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW The...

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on September 13, 2023 at 3:35pm ET in New York. A live...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-14 15:20:44 ET 2seventy bio press release ( NASDAQ: TSVT ): Q2 GAAP EPS of -$0.83. Revenue of $36.04M (+167.4% Y/Y). For further details see: 2seventy bio GAAP EPS of -$0.83, revenue of $36.04M

2023-08-14 11:02:08 ET 2seventy bio, Inc. (TSVT) Q2 2023 Earnings Conference Call August 14, 2023, 08:00 AM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President and Chief Executive Officer Philip Gregory - Chief Scientific Offic...

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. ...

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New York. About 2seventy bio Our name...

2023-07-28 09:47:07 ET More on 2seventy bio 2seventy bio: Nothing Properly Explains The Low Valuation 2seventy bio posts Phase 1 results for CAR-T therapy in bone marrow cancer Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expa...